ACI Worldwide to Participate in Upcoming Investor Conferences
Get Alerts ACIW Hot Sheet
Join SI Premium – FREE
OMAHA, Neb.--(BUSINESS WIRE)-- ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced that company management will participate in the following investor conferences:
KeyBanc Technology Leadership Forum, Park City, UT on August 11 (President and CEO Thomas Warsop, CFO Bobby Leibrock, and SVP John Kraft)
Seaport Research Partners Annual Summer Investor Conference, Virtual on August 18 (CFO Bobby Leibrock and SVP John Kraft)
FT Partners FinTech Conference, New York City on September 15 (President and CEO Thomas Warsop, CFO Bobby Leibrock, and SVP John Kraft)
About ACI Worldwide
ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With more than 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.
© Copyright ACI Worldwide, Inc. 2026
ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay ONE and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties' trademarks referenced are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260805392763/en/
For more information contact:
Investor Relations
John Kraft
SVP, Head of Strategy and Finance
305-894-2223 / [email protected]
Source: ACI Worldwide
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UK Credit Card Payment Rates Drop and Card Balances Rise as Summer Spending Puts Pressure on Consumers
- Festi hf.: Transactions in relation to a share repurchase programme - week 34
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
KeyBancSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share